EUCTR2013-004737-33-FR进行中（未招募）1 期
A prospective, multicenter, randomized, open-label study of 12 week duration to evaluate the effect of VILDagliptin added to insulin on glycaemic control in haemoDIALyzed patients with type 2 diabetes: probe analysis of CGM - VILDDIA
Hôpitaux Universitaires de Strasbourg0 个研究点目标入组 70 人开始时间: 2015年9月25日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •- Patients treated by haemodialysis for more than 3 months with 1g/L glucose in dialysate fluid
- •- Patients treated by stable doses of insulin (any regimen) for Type 2 diabetes without any oral antidiabetic agent
- •- Age > 18 and < 83 years
- •- HbA1c > 7%
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 60
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •- Variability in EPO doses > 20% of doses (U/Kg/Month) or blood transfusion in the 2 previous months
- •- Life expectancy less than 1 year
- •- Chronic inflammatory disease
- •- Steroid treatment
- •- Cancer (evolutive or requiring chemotherapy or radiotherapy)
- •- Patient waiting for programmed surgery
- •- History of cardiovascular disease (stroke, coronary heart disease, hospitalization for heart failure) in the 4 previous months
- •- Non-compliant patients
研究者
相似试验
进行中（未招募）
不适用
A prospective, multicenter, randomized, open-label, active-controlled, 2-parallel group, phase III study to compare efficacy and safety of masitinib at 7.5 mg/kg/day to imatinib at 400 or 600 mg in treatment of patients with gastro-intestinal stromal tumour in first line medical treatmentEUCTR2008-000973-40-HUAB SCIENCE222
招募中
3 期
A prospective, multicenter, randomized, open-label, active-controlled, phase III study to compare efficacy and safety of masitinib to imatinib at 400 or 600 mg in treatment of patients with gastro-intestinal stromal tumour in first line medical treatmentGISTNL-OMON44826AB Science20
进行中（未招募）
1 期
A prospective, multicenter, randomized, open-label, active-controlled, two-parallel groups, phase 3 study to compare the efficacy and safety of masitinib at 7.5 mg/kg/day to dacarbazine in the treatment of patients with non-resectable or metastatic stage 3 or stage 4 melanoma carrying a mutation in the juxta membrane domain of c-kit - Not applicablePatients with non-resectable or metastatic stage 3 or stage 4 melanoma carrying a mutation in the juxta membrane domain of c-kitMedDRA version: 13.1Level: PTClassification code 10025671Term: Malignant melanoma stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 13.1Level: PTClassification code 10025670Term: Malignant melanoma stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-017918-69-SKAB Science200
暂停
不适用
A study to evaluate the efficacy and safety of Aceinavir combined with supportive Standard of Care (SoC) in hospitalized patients with moderate coronavirus disease (COVID-19)CTRI/2020/08/027284Dyuthi Biosciences Private Limited
进行中（未招募）
1 期
A prospective, multicenter, randomized, open-label, active-controlled, two-parallel groups, phase 3 study to compare the efficacy and safety of masitinib at 7.5 mg/kg/day to dacarbazine in the treatment of patients with non-resectable or metastatic stage 3 or stage 4 melanoma carrying a mutation in the juxta membrane domain of c-kit - Not applicablePatients with non-resectable or metastatic stage 3 or stage 4 melanoma carrying a mutation in the juxta membrane domain of c-kitMedDRA version: 19.1Level: PTClassification code 10025671Term: Malignant melanoma stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.1Level: PTClassification code 10025670Term: Malignant melanoma stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-017918-69-ATAB Science78